Skip to main content

MoneyWorks4Me

Claris Lifesciences undergoes USFDA audit for Pharmacovigilance

01 Jun 2017 Evaluate

Claris Lifesciences (CLL) along with its wholly owned subsidiary Claris Injectables (CIL) has underwent a successful USFDA Pharmacovigilance (PV) audit from May 29 to May 31 with No Observation (i483s).

Claris Lifesciences is engaged in manufacturing of drugs and pharmaceutical products. The Company manufactures and markets products across multiple delivery systems, markets and therapeutic segments, including anesthesia and analgesics, blood products, anti-invective's, critical care, and nephrology.

Peers
Company Name CMP
Redington 359.55
Adani Enterprises 2733.00
Amrapali Industries 33.62
Maxgrow India 182.35
Rashi Peripheral 696.70
View more..